Muutke küpsiste eelistusi

E-raamat: Recent Advances in the Pathogenesis and Treatment of Kidney Diseases

Series edited by , Edited by
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 326,04 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

This volume contains 14 papers by nephrologists and other medical specialists from Japan, who describe recent advances in the pathogenesis and treatment of kidney diseases. They address the role of caveolae in albumin passage through glomerular endothelial and epithelial cells; rituximab as a therapeutic option for steroid-sensitive minimal change nephrotic syndrome in adults; the clinical significance of evaluation of the largest renal corpuscle in kidney biopsy specimens; cystic kidney diseases; treatment strategies for lupus nephritis; the association between increases in normalized protein catabolic rate and increases in the creatinine generation rate in dialysis patients; renal anemia and iron metabolism; cell sheet engineering in the treatment of kidney diseases; the clinical impact of left ventricular diastolic dysfunction in chronic kidney disease; treatment of posttransplantation anemia; the role of frailty in outcomes of dialysis patients; the cost effectiveness of administering rituximab for nephrotic syndrome; the relationship between the use of beta-blockers on maintenance dialysis patients and ischemic cerebral and cardiovascular deaths; and the direct effects of immunomodulatory agents on podocytes in immune-mediated glomerular diseases. Annotation ©2018 Ringgold, Inc., Portland, OR (protoview.com)